Increased miR-20b Level in High Grade Cervical Intraepithelial Neoplasia.
Cervical cancer
Cervical intraepithelial neoplasia (CIN)
Human papilloma virus
microRNA
Journal
Pathology oncology research : POR
ISSN: 1532-2807
Titre abrégé: Pathol Oncol Res
Pays: Switzerland
ID NLM: 9706087
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
06
02
2020
accepted:
11
06
2020
pubmed:
10
7
2020
medline:
13
7
2021
entrez:
10
7
2020
Statut:
ppublish
Résumé
Cervical cancer is a common malignant tumor worldwide ranking fourth in incidence and mortality among females, which was reduced significantly by cytology screening and human papilloma virus (HPV) DNA testing. The specificity of cytology is high; however, the sensitivity is low, in contrast to the HPV DNA testing. Despite the success of these measures, new biomarkers are still considered to aim increasing sensitivity and specificity of screening and diagnosis. Significant alterations in microRNA (miRNA) expression have been detected in several cancers with variable consistency. To investigate the stratification role of miRNAs between normal epithelium and cervical intraepithelial neoplasia (CIN2-3), we screened the expression of 667 miRNAs to identify significant markers (n = 10), out of them 9 miRNAs were applied in the study (miR-20b, -24, -26a, -29b, -99a, -100, -147, -212, -515-3p) along with RNU48 and U6 as the references. To benchmark the miRNAs, 22 paired (tumor-free and tumor tissue pairs) laser microdissection-obtained cervical formalin fixed, paraffin embedded tissue samples were assayed. The expression of miR-20b was 2.4 times higher in CIN2-3 samples as compared to normal tissues (p < 0.0001). In the HPV16-positive subsets of the samples (n = 13), miR-20b showed 2.9-times elevation (p < 0.001), whereas miR-515 was 1.15-times downregulated (p < 0.05) in CIN2-3 as compared to normal tissue. These results suggest the potential value of miR-20b as a statification biomarker in order to differentiate neoplastic and non-tumorous cases.
Identifiants
pubmed: 32643116
doi: 10.1007/s12253-020-00852-w
pii: 10.1007/s12253-020-00852-w
pmc: PMC7471155
doi:
Substances chimiques
Biomarkers, Tumor
0
MIRN20b microRNA, human
0
MicroRNAs
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2633-2640Subventions
Organisme : Hungarian Ministry of National Development
ID : #KMR-12-A FP7-HEALTH-2012-INNOVATION-1-Grant Agreement Number 306037
Organisme : Hungarian National Research Foundation
ID : OTKA PD105019
Références
Anticancer Res. 2015 Jan;35(1):523-30
pubmed: 25550598
BMC Cancer. 2018 Jun 27;18(1):696
pubmed: 29945565
Int J Cancer. 2016 Mar 15;138(6):1312-27
pubmed: 26032913
BMC Bioinformatics. 2013 Apr 15;14:128
pubmed: 23586463
Oncol Lett. 2018 Jun;15(6):9994-10000
pubmed: 29928371
J Biomed Inform. 2011 Oct;44(5):839-47
pubmed: 21605702
PLoS One. 2008 Jul 02;3(7):e2557
pubmed: 18596939
Cell Signal. 2019 Oct;62:109350
pubmed: 31254605
Mol Med Rep. 2020 Jan;21(1):209-219
pubmed: 31746391
Lancet. 2014 Feb 8;383(9916):493-4
pubmed: 24192251
Mol Med Rep. 2017 Oct;16(4):5464-5470
pubmed: 28849054
Cancer Res. 2004 Aug 1;64(15):5245-50
pubmed: 15289330
Cell Cycle. 2012 Aug 1;11(15):2876-84
pubmed: 22801550
Mol Oncol. 2018 Dec;12(12):2009-2022
pubmed: 30221475
Life Sci. 2019 Sep 1;232:116668
pubmed: 31326568
J Gynecol Oncol. 2017 Nov;28(6):e75
pubmed: 29027393
Oncotarget. 2016 Oct 18;7(42):68397-68411
pubmed: 27588393
Oncol Rep. 2016 Jan;35(1):3-12
pubmed: 26530778
Proc Natl Acad Sci U S A. 2014 Mar 18;111(11):4262-7
pubmed: 24591631
Lab Med. 2018 Mar 21;49(2):97-111
pubmed: 29378033
J Natl Cancer Inst. 2013 Oct 16;105(20):1524-6
pubmed: 24096622
PLoS One. 2018 Jul 18;13(7):e0200717
pubmed: 30020984
Gynecol Oncol. 2016 Sep;142(3):557-65
pubmed: 27423381
Anticancer Res. 2013 Jun;33(6):2561-7
pubmed: 23749909
Int J Cancer. 2017 Mar 1;140(5):1119-1133
pubmed: 27874187
Biomed Res Int. 2013;2013:519619
pubmed: 24383054
Int J Mol Sci. 2015 Jun 05;16(6):12773-90
pubmed: 26057746
Onco Targets Ther. 2019 Aug 26;12:6917-6925
pubmed: 31692593
Lancet. 2013 Sep 7;382(9895):889-99
pubmed: 23618600
J Cell Biochem. 2019 Sep;120(9):15834-15843
pubmed: 31081157
PLoS One. 2010 Jul 26;5(7):e11780
pubmed: 20668671
Mod Pathol. 2020 Jan;33(1):128-137
pubmed: 31492932
Sci Rep. 2018 May 4;8(1):7070
pubmed: 29728572
Oncol Lett. 2018 Nov;16(5):5679-5686
pubmed: 30344723
Cancer J. 2012 May-Jun;18(3):215-22
pubmed: 22647357
Oncol Lett. 2016 Jan;11(1):405-410
pubmed: 26870225
Lancet. 2014 Feb 8;383(9916):524-32
pubmed: 24192252
Vaccine. 2012 Nov 20;30 Suppl 5:F88-99
pubmed: 23199969
Pathol Oncol Res. 2015 Jul;21(3):503-8
pubmed: 25601525
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
JAMA. 2002 Apr 24;287(16):2114-9
pubmed: 11966386
Oncotarget. 2017 Feb 28;8(9):14655-14665
pubmed: 28122338
Oncol Lett. 2018 Oct;16(4):5200-5208
pubmed: 30250588
Springerplus. 2016 Oct 22;5(1):1856
pubmed: 27818894
Biochim Biophys Acta Rev Cancer. 2019 Dec;1872(2):188306
pubmed: 31398380